[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.173.230. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
August 1, 2001

Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial—Correction

JAMA. 2001;286(5):536. doi:10.1001/jama.286.5.536

Incorrect Numbers. The Original Contribution entitled "Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial" published in the April 4, 2001, issue of THE JOURNAL (2001;285:1711-1718) contained some incorrect numbers. On page 1715, in the first full paragraph in column 1, the third and fourth sentences should be replaced with: "Among patents who had baseline LDL cholesterol levels of less than or equal to the median value of 121 mg/dL (3.1 mmol/L), primary end point events occurred in 113 (15.0%) of 752 patients in the atorvastatin group and 136 (18.7%) of 729 patients in the placebo group (RR, 0.77; 95% CI, 0.59-0.98). Among patients who had baseline LDL cholesterol levels greater than the median value, primary end point events occurred in 109 (15.0%) of 726 patients in the atorvastatin group and 124 (16.6%) of 749 patients in the placebo group (RR, 0.92; 95% CI, 0.71-1.19). One hundred thirty patients did not have a complete set of baseline lipid measurements by the central laboratory and are not included in this analysis."

×